AstraZeneca Plc said it temporarily halted two trials combining cancer drugs due to reports of lung disease.
The company stopped tests that combined its AZD9291 compound with durvalumab to treat patients with advanced non-small cell lung cancer after an increase in the incidence of interstitial lung disease-like reports, spokeswoman Esra Erkal-Paler said by e-mail, confirming a note to investors from Goldman Sachs Group Inc.
